JAK2 inhibitors for myelofibrosis: Why are they effective in patients with and without JAK2V617F mutation?

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 1098-1109

  Santos, Fabio P S ^a   Verstovsek, Srdan ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Essential thrombocythemia; JAK2 inhibitor; JAK2V617F; Myelofibrosis; Polycythemia vera

Indexed keywords

BMS 911543; CYTOKINE; CYTOKINE RECEPTOR; ERYTHROPOIETIN RECEPTOR; GANDOTINIB; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; JANUS KINASE 3; MOMELOTINIB; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL) ETHOXY] PHENYLAMINO] 4 PYRIMIDINYLAMINO] BENZENESULFONAMIDE; N TERT BUTYL 3 [5 METHYL 2 [4 [2 (1 PYRROLIDINYL)ETHOXY]PHENYLAMINO] 4 PYRIMIDINYLAMINO]BENZENESULFONAMIDE; NS 018; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; RAS PROTEIN; RUXOLITINIB; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; GENE MUTATION; HEADACHE; HUMAN; HYPERKALEMIA; HYPERURICEMIA; MYELOFIBROSIS; MYELOPROLIFERATIVE NEOPLASM; NAUSEA; NEUTROPENIA; NONHUMAN; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; THROMBOCYTHEMIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR LYSIS SYNDROME; UROSEPSIS; VOMITING;

ANIMALS; BENZAMIDES; CYTOKINES; HUMANS; IMIDAZOLES; JANUS KINASE 2; POINT MUTATION; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDAZINES; PYRIMIDINES; PYRROLIDINES; SULFONAMIDES;

EID: 84872260963     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803529727     Document Type: Article

References (93)

1. Thiele, J.; Kvasnicka, H. M.; Tefferi, A.; Barosi, G.; Orazi, A.; Vardiman, J. W.: Primary Myelofibrosis. In World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues; Swerdlow, S. H., Campo, E., Harris, N. L., Jaffe, E. S., Pileri, S. A., Stein, H., Thiele, J., Vardiman, J. W., Eds.; IARC Press: Lyon, 2008; pp 44-47.
2. Mesa, R. A.; Verstovsek, S.; Cervantes, F.; Barosi, G.; Reilly, J. T.; Dupriez, B.; Levine, R.; Le Bousse-Kerdiles, M. C.; Wadleigh, M.; Campbell, P. J.; Silver, R. T.; Vannucchi, A. M.; Deeg, H. J.; Gisslinger, H.; Thomas, D.; Odenike, O.; Solberg, L. A.; Gotlib, J.; Hexner, E.; Nimer, S. D.; Kantarjian, H.; Orazi, A.; Vardiman, J. W.; Thiele, J.; Tefferi, A. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res., 2007, 31(6), 737-740.
3. Baxter, E. J.; Scott, L. M.; Campbell, P. J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G. S.; Bench, A. J.; Boyd, E. M.; Curtin, N.; Scott, M. A.; Erber, W. N.; Green, A. R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, 365(9464), 1054-1061.
4. James, C.; Ugo, V.; Le Couedic, J. P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garcon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; Villeval, J. L.; Constantinescu, S. N.; Casadevall, N.; Vainchenker, W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434(7037), 1144-1148.
5. Kralovics, R.; Passamonti, F.; Buser, A. S.; Teo, S. S.; Tiedt, R.; Passweg, J. R.; Tichelli, A.; Cazzola, M.; Skoda, R. C. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med., 2005, 352(17), 1779-1790.
6. Levine, R. L.; Wadleigh, M.; Cools, J.; Ebert, B. L.; Wernig, G.; Huntly, B. J.; Boggon, T. J.; Wlodarska, I.; Clark, J. J.; Moore, S.; Adelsperger, J.; Koo, S.; Lee, J. C.; Gabriel, S.; Mercher, T.; D'Andrea, A.; Frohling, S.; Dohner, K.; Marynen, P.; Vandenberghe, P.; Mesa, R. A.; Tefferi, A.; Griffin, J. D.; Eck, M. J.; Sellers, W. R.; Meyerson, M.; Golub, T. R.; Lee, S. J.; Gilliland, D. G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7(4), 387-397.
7. Pikman, Y.; Lee, B. H.; Mercher, T.; McDowell, E.; Ebert, B. L.; Gozo, M.; Cuker, A.; Wernig, G.; Moore, S.; Galinsky, I.; DeAngelo, D. J.; Clark, J. J.; Lee, S. J.; Golub, T. R.; Wadleigh, M.; Gilliland, D. G.; Levine, R. L. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 2006, 3(7), e270.
8. Scott, L. M.; Tong, W.; Levine, R. L.; Scott, M. A.; Beer, P. A.; Stratton, M. R.; Futreal, P. A.; Erber, W. N.; McMullin, M. F.; Harrison, C. N.; Warren, A. J.; Gilliland, D. G.; Lodish, H. F.; Green, A. R. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med., 2007, 356(5), 459-468.
9. Anand, S.; Stedham, F.; Gudgin, E.; Campbell, P.; Beer, P.; Green, A. R.; Huntly, B. J. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms. Blood, 2011, 118(6), 1610-1621.
10. Tefferi, A.; Vaidya, R.; Caramazza, D.; Finke, C.; Lasho, T.; Pardanani, A. Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. J. Clin. Oncol., 2011, 29(10), 1356-1363.
11. Wilks, A. F. Two putative protein-tyrosine kinases identified by application of the polymerase chain reaction. Proc. Natl. Acad. Sci. U.S.A., 1989, 86(5), 1603-1607.
12. Giordanetto, F.; Kroemer, R. T. Prediction of the structure of human Janus kinase 2 (JAK2) comprising JAK homology domains 1 through 7. Protein Eng., 2002, 15(9), 727-737.
13. Saharinen, P.; Silvennoinen, O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem., 2002, 277(49), 47954-47963.
14. Ungureanu, D.; Wu, J.; Pekkala, T.; Niranjan, Y.; Young, C.; Jensen, O. N.; Xu, C. F.; Neubert, T. A.; Skoda, R. C.; Hubbard, S. R.; Silvennoinen, O. The pseudokinase domain of JAK2 is a dualspecificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol., 2011, 18(9), 971-976.
15. Leonard, W. J.; O'Shea, J. J. Jaks and STATs: biological implications. Annu. Rev. Immunol., 1998, 16, 293-322.
16. Murray, P. J. The JAK-STAT signaling pathway: input and output integration. J. Immunol., 2007, 178(5), 2623-2629.
17. Rodig, S. J.; Meraz, M. A.; White, J. M.; Lampe, P. A.; Riley, J. K.; Arthur, C. D.; King, K. L.; Sheehan, K. C.; Yin, L.; Pennica, D.; Johnson, E. M., Jr.; Schreiber, R. D. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell, 1998, 93(3), 373-383.
18. Lutticken, C.; Wegenka, U. M.; Yuan, J.; Buschmann, J.; Schindler, C.; Ziemiecki, A.; Harpur, A. G.; Wilks, A. F.; Yasukawa, K.; Taga, T.; Kishimoto, T.; Barbieri, G.; Pellegrini, S.; Sendtner, M.; Heinrich, P.C.; Horn, Friedemann. Association of Transcription Factor APRF and Protein Kinase Jak1 with the Interleukin-6 Signal Transducer gp130. Science, 1994, 263 (5143), 89-92.
19. Neubauer, H.; Cumano, A.; Muller, M.; Wu, H.; Huffstadt, U.; Pfeffer, K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell, 1998, 93(3), 397-409.
20. Parganas, E.; Wang, D.; Stravopodis, D.; Topham, D. J.; Marine, J. C.; Teglund, S.; Vanin, E. F.; Bodner, S.; Colamonici, O. R.; van Deursen, J. M.; Grosveld, G.; Ihle, J. N. Jak2 is essential for signaling through a variety of cytokine receptors. Cell, 1998, 93(3), 385-395.
21. Nosaka, T.; van Deursen, J. M.; Tripp, R. A.; Thierfelder, W. E.; Witthuhn, B. A.; McMickle, A. P.; Doherty, P. C.; Grosveld, G. C.; Ihle, J. N. Defective lymphoid development in mice lacking Jak3. Science, 1995, 270(5237), 800-802.
22. Thomis, D. C.; Gurniak, C. B.; Tivol, E.; Sharpe, A. H.; Berg, L. J. Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3. Science, 1995, 270(5237), 794-797.
23. Macchi, P.; Villa, A.; Giliani, S.; Sacco, M. G.; Frattini, A.; Porta, F.; Ugazio, A. G.; Johnston, J. A.; Candotti, F.; O'Shea, J. J.; et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature, 1995, 377(6544), 65-68.
24. Russell, S. M.; Tayebi, N.; Nakajima, H.; Riedy, M. C.; Roberts, J. L.; Aman, M. J.; Migone, T. S.; Noguchi, M.; Markert, M. L.; Buckley, R. H.; O'Shea, J. J.; Leonard, W. J. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science, 1995, 270(5237), 797-800.
25. Karaghiosoff, M.; Neubauer, H.; Lassnig, C.; Kovarik, P.; Schindler, H.; Pircher, H.; McCoy, B.; Bogdan, C.; Decker, T.; Brem, G.; Pfeffer, K.; Muller, M. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity, 2000, 13(4), 549-560.
26. Shimoda, K.; Kato, K.; Aoki, K.; Matsuda, T.; Miyamoto, A.; Shibamori, M.; Yamashita, M.; Numata, A.; Takase, K.; Kobayashi, S.; Shibata, S.; Asano, Y.; Gondo, H.; Sekiguchi, K.; Nakayama, K.; Nakayama, T.; Okamura, T.; Okamura, S.; Niho, Y. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function. Immunity, 2000, 13(4), 561-571.
27. Shaw, M. H.; Freeman, G. J.; Scott, M. F.; Fox, B. A.; Bzik, D. J.; Belkaid, Y.; Yap, G. S. Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFNgamma-dependent IL-10 reactivation. J. Immunol., 2006, 176(12), 7263-7271.
28. Lai, C. F.; Ripperger, J.; Morella, K. K.; Wang, Y.; Gearing, D. P.; Fey, G. H.; Baumann, H. Separate signaling mechanisms are involved in the control of STAT protein activation and gene regulation via the interleukin 6 response element by the box 3 motif of gp130. J. Biol. Chem., 1995, 270(25), 14847-14850.
29. Vainchenker, W.; Delhommeau, F.; Constantinescu, S. N.; Bernard, O. A. New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 2011, 118(7), 1723-1735.
30. Lacout, C.; Pisani, D. F.; Tulliez, M.; Gachelin, F. M.; Vainchenker, W.; Villeval, J. L. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood, 2006, 108(5), 1652-1660.
31. Wernig, G.; Mercher, T.; Okabe, R.; Levine, R. L.; Lee, B. H.; Gilliland, D. G. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood, 2006, 107(11), 4274-4281.
32. Bumm, T. G.; Elsea, C.; Corbin, A. S.; Loriaux, M.; Sherbenou, D.; Wood, L.; Deininger, J.; Silver, R. T.; Druker, B. J.; Deininger, M. W. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res., 2006, 66(23), 11156-11165.
33. Zaleskas, V. M.; Krause, D. S.; Lazarides, K.; Patel, N.; Hu, Y.; Li, S.; Van Etten, R. A. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F. PLoS One, 2006, 1(e18.
34. Xing, S.; Wanting, T. H.; Zhao, W.; Ma, J.; Wang, S.; Xu, X.; Li, Q.; Fu, X.; Xu, M.; Zhao, Z. J. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood, 2008, 111(10), 5109-5117.
35. Tiedt, R.; Hao-Shen, H.; Sobas, M. A.; Looser, R.; Dirnhofer, S.; Schwaller, J.; Skoda, R. C. Ratio of mutant JAK2-V617F to wildtype Jak2 determines the MPD phenotypes in transgenic mice. Blood, 2008, 111(8), 3931-3940.
36. Shide, K.; Shimoda, H. K.; Kumano, T.; Karube, K.; Kameda, T.; Takenaka, K.; Oku, S.; Abe, H.; Katayose, K. S.; Kubuki, Y.; Kusumoto, K.; Hasuike, S.; Tahara, Y.; Nagata, K.; Matsuda, T.; Ohshima, K.; Harada, M.; Shimoda, K. Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F. Leukemia, 2008, 22(1), 87-95.
37. Mullally, A.; Lane, S. W.; Ball, B.; Megerdichian, C.; Okabe, R.; Al-Shahrour, F.; Paktinat, M.; Haydu, J. E.; Housman, E.; Lord, A. M.; Wernig, G.; Kharas, M. G.; Mercher, T.; Kutok, J. L.; Gilliland, D. G.; Ebert, B. L. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell, 2010, 17(6), 584-596.
38. Akada, H.; Yan, D.; Zou, H.; Fiering, S.; Hutchison, R. E.; Mohi, M. G. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood, 2010, 115(17), 3589-3597.
39. Li, J.; Spensberger, D.; Ahn, J. S.; Anand, S.; Beer, P. A.; Ghevaert, C.; Chen, E.; Forrai, A.; Scott, L. M.; Ferreira, R.; Campbell, P. J.; Watson, S. P.; Liu, P.; Erber, W. N.; Huntly, B. J.; Ottersbach, K.; Green, A. R. JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. Blood, 2010, 116(9), 1528-1538.
40. Marty, C.; Lacout, C.; Martin, A.; Hasan, S.; Jacquot, S.; Birling, M. C.; Vainchenker, W.; Villeval, J. L. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood, 2010, 116(5), 783-787.
41. Dawson, M. A.; Bannister, A. J.; Gottgens, B.; Foster, S. D.; Bartke, T.; Green, A. R.; Kouzarides, T. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin. Nature, 2009, 461(7265), 819-822.
42. Beer, P. A.; Campbell, P. J.; Scott, L. M.; Bench, A. J.; Erber, W. N.; Bareford, D.; Wilkins, B. S.; Reilly, J. T.; Hasselbalch, H. C.; Bowman, R.; Wheatley, K.; Buck, G.; Harrison, C. N.; Green, A. R. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood, 2008, 112(1), 141-149.
43. Chaligne, R.; Tonetti, C.; Besancenot, R.; Roy, L.; Marty, C.; Mossuz, P.; Kiladjian, J. J.; Socie, G.; Bordessoule, D.; Le Bousse-Kerdiles, M. C.; Vainchenker, W.; Giraudier, S. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia, 2008, 22(8), 1557-1566.
44. Thien, C. B.; Langdon, W. Y. c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses. Biochem. J., 2005, 391(Pt 2), 153-166.
45. Thien, C. B.; Langdon, W. Y. Negative regulation of PTK signalling by Cbl proteins. Growth Factors, 2005, 23(2), 161-167.
46. Grand, F. H.; Hidalgo-Curtis, C. E.; Ernst, T.; Zoi, K.; Zoi, C.; McGuire, C.; Kreil, S.; Jones, A.; Score, J.; Metzgeroth, G.; Oscier, D.; Hall, A.; Brandts, C.; Serve, H.; Reiter, A.; Chase, A. J.; Cross, N. C. Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms. Blood, 2009, 113(24), 6182-6192.
47. Oh, S. T.; Simonds, E. F.; Jones, C.; Hale, M. B.; Goltsev, Y.; Gibbs, K. D., Jr.; Merker, J. D.; Zehnder, J. L.; Nolan, G. P.; Gotlib, J. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood, 2010, 116(6), 988-992.
48. Lasho, T. L.; Pardanani, A.; Tefferi, A. LNK mutations in JAK2 mutation-negative erythrocytosis. N. Engl. J. Med., 2010, 363(12), 1189-1190.
49. Bersenev, A.; Wu, C.; Balcerek, J.; Jing, J.; Kundu, M.; Blobel, G. A.; Chikwava, K. R.; Tong, W. Lnk constrains myeloproliferative diseases in mice. J. Clin. Invest., 2010, 120(6), 2058-2069.
50. Pardanani, A.; Lasho, T.; Finke, C.; Oh, S. T.; Gotlib, J.; Tefferi, A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia, 2010, 24(10), 1713-1718.
51. Quintas-Cardama, A.; Vaddi, K.; Liu, P.; Manshouri, T.; Li, J.; Scherle, P. A.; Caulder, E.; Wen, X.; Li, Y.; Waeltz, P.; Rupar, M.; Burn, T.; Lo, Y.; Kelley, J.; Covington, M.; Shepard, S.; Rodgers, J. D.; Haley, P.; Kantarjian, H.; Fridman, J. S.; Verstovsek, S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.
52. Hexner, E. O.; Serdikoff, C.; Jan, M.; Swider, C. R.; Robinson, C.; Yang, S.; Angeles, T.; Emerson, S. G.; Carroll, M.; Ruggeri, B.; Dobrzanski, P. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood, 2008, 111(12), 5663-5671.
53. Krause, D. S.; Van Etten, R. A. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med., 2005, 353(2), 172-187.
54. Ciurea, S. O.; Merchant, D.; Mahmud, N.; Ishii, T.; Zhao, Y.; Hu, W.; Bruno, E.; Barosi, G.; Xu, M.; Hoffman, R. Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood, 2007, 110(3), 986-993.
55. Lundberg, L. G.; Lerner, R.; Sundelin, P.; Rogers, R.; Folkman, J.; Palmblad, J. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am. J. Pathol., 2000, 157(1), 15-19.
56. Emadi, S.; Clay, D.; Desterke, C.; Guerton, B.; Maquarre, E.; Charpentier, A.; Jasmin, C.; Le Bousse-Kerdiles, M. C. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood, 2005, 105(2), 464-473.
57. Panteli, K. E.; Hatzimichael, E. C.; Bouranta, P. K.; Katsaraki, A.; Seferiadis, K.; Stebbing, J.; Bourantas, K. L. Serum interleukin (IL)-1, IL-2, sIL-2Ra, IL-6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. Br. J. Haematol., 2005, 130(5), 709-715.
58. Rameshwar, P.; Denny, T. N.; Stein, D.; Gascon, P. Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta. J. Immunol., 1994, 153(6), 2819-2830.
59. Rameshwar, P.; Narayanan, R.; Qian, J.; Denny, T. N.; Colon, C.; Gascon, P. NF-kappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J. Immunol., 2000, 165(4), 2271-2277.
60. Steurer, M.; Zoller, H.; Augustin, F.; Fong, D.; Heiss, S.; Strasser-Weippl, K.; Gastl, G.; Tzankov, A. Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. Hum. Pathol., 2007, 38(7), 1057-1064.
61. Wang, J. C.; Hemavathy, K.; Charles, W.; Zhang, H.; Dua, P. K.; Novetsky, A. D.; Chang, T.; Wong, C.; Jabara, M. Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). Exp. Hematol., 2004, 32(10), 905-910.
62. Manshouri, T.; Estrov, Z.; Quintas-Cardama, A.; Burger, J.; Zhang, Y.; Livun, A.; Knez, L.; Harris, D.; Creighton, C. J.; Kantarjian, H. M.; Verstovsek, S. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor. Cancer Res., 2011, 71(11), 3831-3840.
63. Jedidi, A.; Marty, C.; Oligo, C.; Jeanson-Leh, L.; Ribeil, J. A.; Casadevall, N.; Galy, A.; Vainchenker, W.; Villeval, J. L. Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood, 2009, 114(9), 1842-1851.
64. Mesa, R.; Gale, R. P. Hypothesis: how do JAK2-inhibitors work in myelofibrosis. Leuk. Res., 2009, 33(9), 1156-7.
65. Vannucchi, A. M. How do JAK2-inhibitors work in myelofibrosis: an alternative hypothesis. Leuk. Res., 2009, 33(12), 1581-1583.
66. Verstovsek, S.; Kantarjian, H.; Mesa, R. A.; Pardanani, A. D.; Cortes-Franco, J.; Thomas, D. A.; Estrov, Z.; Fridman, J. S.; Bradley, E. C.; Erickson-Viitanen, S.; Vaddi, K.; Levy, R.; Tefferi, A. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med., 2010, 363(12), 1117-1127.
67. Verstovsek, S.; Mesa, R. A.; Gotlib, J.; Levy, R.; Gupta, V.; diPersio, J. F.; Catalano, J.; Deininger, M. W.; MIller, C. B.; Silver, R. T.; Talpaz, M.; Winton, E. F.; Harvey Jr., J.; Arcasoy, M. O.; Hexner, E.; Lyons, R. M.; Paquette, R. L.; Raza, A.; Vaddi, K.; Erickson-Viitanen, S.; Sun, W.; Sandor, V. A.; Kantarjian, H. Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I [abstract]. Blood, 2011, 118(21), Abstract 278.
68. Quintas-Cardama, A.; Vaddi, K.; Liu, P.; Manshouri, T.; Li, J.; Scherle, P. A.; Caulder, E.; Wen, X.; Li, Y.; Waeltz, P.; Rupar, M.; Burn, T.; Lo, Y.; Kelley, J.; Covington, M.; Shepard, S.; Rodgers, J. D.; Haley, P.; Kantarjian, H.; Fridman, J. S.; Verstovsek, S. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood, 2010, 115(15), 3109-3117.
69. Tefferi, A.; Barosi, G.; Mesa, R. A.; Cervantes, F.; Deeg, H. J.; Reilly, J. T.; Verstovsek, S.; Dupriez, B.; Silver, R. T.; Odenike, O.; Cortes, J.; Wadleigh, M.; Solberg, L. A., Jr.; Camoriano, J. K.; Gisslinger, H.; Noel, P.; Thiele, J.; Vardiman, J. W.; Hoffman, R.; Cross, N. C.; Gilliland, D. G.; Kantarjian, H. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 2006, 108(5), 1497-1503.
70. Mesa, R. A.; Schwager, S.; Radia, D.; Cheville, A.; Hussein, K.; Niblack, J.; Pardanani, A. D.; Steensma, D. P.; Litzow, M. R.; Rivera, C. E.; Camoriano, J.; Verstovsek, S.; Sloan, J.; Harrison, C.; Kantarjian, H.; Tefferi, A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk. Res., 2009, 33(9), 1199-1203.
71. Verstovsek, S.; Estrov, Z.; Cortes, J.; Thomas, D.; Borthakur, G.; Kadia, T.; Jabbour, E.; Pierce, S.; Kantarjian, H. The MD Anderson Cancer Center (MDACC) Experience with Ruxolitinib, An Oral JAK1 and JAK2 Inhibitor, in Myelofibrosis: Long-Term Follow-up Outcomes of 107 Patients From a Phase I/II Study [abstract]. Blood, 2011, 118(21), Abstract 3851.
72. Verstovsek, S.; Kantarjian, H.; Estrov, Z.; Cortes, J.; Thomas, D.; Kadia, T.; Pierce, S.; Cazzola, M.; Rumi, E.; Morra, E.; Pungolino, E.; Caramazza, D.; Passamonti, F. Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy [abstract]. Blood, 2011, 118(21), Abstract 793.
73. Tefferi, A.; Litzow, M. R.; Pardanani, A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N. Engl. J. Med., 2011, 365(15), 1455-1457.
74. Tefferi, A.; Pardanani, A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo. Clin. Proc., 2011, 86(12), 1188-1191.
75. Harrison, C. N.; Kiladijan, J. J.; Al-Ali, H. K.; Gisslinger, H.; Waltzman, R. J.; Stalbovskaya, V.; McQuitty, M.; Hunter, D. S.; Levy, R.; Cervantes, F.; Vannucchi, A. M.; Barbui, T.; Barosi, G. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPVMF) or post-essential thrombocythemia-myelofibrosis (PET-MF). J. Clin. Oncol., 2011, 29(Suppl), Abstract LBA6501.
76. Verstovsek, S.; Mesa, R.; Gotlib, J.; Levy, R.; Gupta, V.; diPersio, J. F.; Catalano, J.; Deininger, M. W.; MIller, C. B.; Silver, R. T.; Talpaz, M.; Winton, E. F.; Harvey, J. H.; Vaddi, K.; Erickson-Viitanen, S.; Koumenis, I.; Sun, W.; Sandor, V.; Kantarjian, H. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). J. Clin. Oncol., 2011, 299(Suppl), Abstract 6500.
77. "U.S. Food and Drug Administration: Report on Approval of Ruxolitinib, " FDA Press Release.
78. Tyner, J. W.; Bumm, T. G.; Deininger, J.; Wood, L.; Aichberger, K. J.; Loriaux, M. M.; Druker, B. J.; Burns, C. J.; Fantino, E.; Deininger, M. W. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood, 2010, 115(25), 5232-5240.
79. Pardanani, A.; Lasho, T.; Smith, G.; Burns, C. J.; Fantino, E.; Tefferi, A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 2009, 23(8), 1441-1445.
80. Pardanani, A.; Gotlib, J.; Gupta, V.; Roberts, A.W.; Wadleigh, M.; Sirhan, S.; Litzow, M.; Hogan, W.J.; Begna, K.; Smith, G.; Bavisotto, L.M.; Kowalski, M.; Tefferi, A. An expanded multicenter phase I/II study of CYT387, a JAK-1/2 inhibitor for the treatment of myelofibrosis [abstract]. Blood, 2011, 118(21), Abstract 3849.
81. Geron, I.; Abrahamsson, A. E.; Barroga, C. F.; Kavalerchik, E.; Gotlib, J.; Hood, J. D.; Durocher, J.; Mak, C. C.; Noronha, G.; Soll, R. M.; Tefferi, A.; Kaushansky, K.; Jamieson, C. H. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell, 2008, 13(4), 321-330.
82. Wernig, G.; Kharas, M. G.; Okabe, R.; Moore, S. A.; Leeman, D. S.; Cullen, D. E.; Gozo, M.; McDowell, E. P.; Levine, R. L.; Doukas, J.; Mak, C. C.; Noronha, G.; Martin, M.; Ko, Y. D.; Lee, B. H.; Soll, R. M.; Tefferi, A.; Hood, J. D.; Gilliland, D. G. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell, 2008, 13(4), 311-320.
83. Pardanani, A.; Gotlib, J. R.; Jamieson, C.; Cortes, J. E.; Talpaz, M.; Stone, R. M.; Silverman, M. H.; Gilliland, D. G.; Shorr, J.; Tefferi, A. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J. Clin. Oncol., 2011, 29(7), 789-796.
84. Pardanani, A.; Gotlib, J.; Jamieson, C.; Cortes, J.; Talpaz, M.; Stone, R.; Gao, G.; Zhang, J.; Neumann, F.; Tefferi, A. SAR302503: Interim Safety, Efficacy and Long-Term Impact on JAK2 V617F Allele Burden in a Phase I/II Study in Patients with Myelofibrosis [abstract]. Blood, 2011, 118(21), Abstract 3838.
85. Ma, L.; Zhao, B.; Walgren, R.; Clayton, J. A.; Blosser, W. D.; Burkholder, T. P.; Smith, M. C. Efficacy of LY2784544, a Small Molecule Inhibitor Selective for Mutant JAK2 Kinase, In JAK2 V617F-Induced Hematologic Malignancy Models [abstract]. Blood, 2010, 116(21), Abstract 4087.
86. Florensa, L.; Bellosillo, B.; Arenillas, L.; Ma, L.; Walgren, R.; Alvarez, A.; Gonzalez, J.; Vila, R. M.; Longaron, R.; Besses, C. LY2784544, a Novel JAK2 Inhibitor, Decreases In Vitro Growth of Hematopoietic Human Progenitors From JAK2 V617F Positive Polycythemia Vera Patients [abstract]. Blood, 2010, 116(21), Abstract 5054.
87. Verstovsek, S.; Mesa, R.; Rhoades, S. K.; Giles, J. L. K.; Pitou, C.; E., J.; Walgren, R.; Prchal, J. F. Phase I Study of the JAK2 V617F Inhibitor, LY2784544, in Patients with Myelofibrosis (MF), Polycythemia Vera (PV), and Essential Thrombocythemia (ET). Blood, 2011, 118(21), Abstract 2814.
88. Nakaya, Y.; Shide, K.; Niwa, T.; Homan, J.; Sugahara, S.; Horio, T.; Kuramoto, K.; Kotera, T.; Shibayama, H.; Hori, K.; Naito, H.; Shimoda, K. Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms. Blood Cancer J., 2011, 1(e29), doi:10.1038/bcj. 2011.29.
89. Purandare, A. V.; McDevitt, T. M.; Wan, H.; You, D.; Penhallow, B.; Han, X.; Vuppugalla, R.; Zhang, Y.; Ruepp, S. U.; Trainor, G. L.; Lombardo, L.; Pedicord, D.; Gottardis, M. M.; Ross-Macdonald, P.; de Silva, H.; Hosbach, J.; Emanuel, S. L.; Blat, Y.; Fitzpatrick, E.; Taylor, T. L.; McIntyre, K. W.; Michaud, E.; Mulligan, C.; Lee, F. Y.; Woolfson, A.; Lasho, T. L.; Pardanani, A.; Tefferi, A.; Lorenzi, M. V. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia, 2011.
90. Verstovsek, S.; Passamonti, F.; Rambaldi, A.; Barosi, G.; Rosen, P. J.; Levy, R.; Bradley, E.; Garrett, W.; Vaddi, K.; Contel, N.; Sandor, V.; Huber, R. M.; Schacter, L. P.; Rumi, E.; Gattoni, E.; Antonioli, E.; Pieri, L.; Cazzola, M.; Kantarjian, H.; Barbui, T.; Vannucchi, A. M. Durable Responses with the JAK1/JAK2 Inhibitor, INCB018424, In Patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory or Intolerant to Hydroxyurea (HU) [abstract]. Blood, 2010, 116(21), Abstract 313.
91. Kiladjian, J. J.; Cassinat, B.; Chevret, S.; Turlure, P.; Cambier, N.; Roussel, M.; Bellucci, S.; Grandchamp, B.; Chomienne, C.; Fenaux, P. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood, 2008, 112(8), 3065-3072.
92. Quintas-Cardama, A.; Kantarjian, H.; Manshouri, T.; Luthra, R.; Estrov, Z.; Pierce, S.; Richie, M. A.; Borthakur, G.; Konopleva, M.; Cortes, J.; Verstovsek, S. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J. Clin. Oncol., 2009, 27(32), 5418-5424.
93. Silver, R. T.; Vandris, K.; Goldman, J. J. Recombinant interferonalpha may retard progression of early primary myelofibrosis: a preliminary report. Blood, 2011, 117(24), 6669-6672.